IMUX - NASDAQ

Immunic, Inc.

IMUX·NASDAQ

$14.43

+0.63%

HealthcareBiotechnology

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$142.40M

EPS-6.2400

P/E Ratio-2.31

Earnings Date08/06/2026

imux

Shares Outstanding

Last Annual Value

15.57M

3-Year CAGR

70%

5-Year CAGR

10-Year CAGR

38%

Adjust for Inflation

Immunic, Inc. Competitors Analysis of shares-outstanding

IMUX · NASDAQ

Company	shares-outstanding	CAGR 3Y	CAGR 5Y	CAGR 10Y
Immunic, Inc. NASDAQ:IMUX	15.57M	52.0%	45.8%	34.8%
Biomea Fusion, Inc. NASDAQ:BMEA	52.23M	15.3%	17.0%	N/A
Werewolf Therapeutics, Inc. NASDAQ:HOWL	46.81M	9.5%	20.5%	N/A
ALX Oncology Holdings Inc. NASDAQ:ALXO	53.66M	7.7%	5.9%	N/A
MindWalk Holdings Corp. NASDAQ:HYFT	33.38M	10.3%	15.2%	32.5%
ImageneBio Inc NASDAQ:IMA	4.87M	-51.1%	-33.0%	N/A
Unicycive Therapeutics, Inc. NASDAQ:UNCY	158.87M	301.5%	167.1%	N/A
Adicet Bio, Inc. NASDAQ:ACET	6.89M	36.8%	28.9%	-13.1%
Lite Strategy, Inc. NASDAQ:LITS	6.66M	0.0%	3.1%	N/A
PMV Pharmaceuticals, Inc. NASDAQ:PMVP	52.54M	3.0%	3.1%	N/A
Relmada Therapeutics, Inc. NASDAQ:RLMD	39.48M	9.5%	17.6%	29.3%

Immunic, Inc. Fair Value Envelope

IMUX · NASDAQ

Our analysis suggests that IMUX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $14.43, this represents a potential HIDDEN relative to our calculated worth for Immunic, Inc..

HIDDEN

Intrinsic Value

Current Price: $14.43

Related Guides

Blog Categories

Continue your IMUX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.